Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

Sorich Michael J.; Rowland Andrew; Kichenadasse GanessanWoodman Richard J.Mangoni Arduino A.

首页> 外文期刊>The British journal of cancer >Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

【24h】

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

机译：接受VEGF抑制剂治疗的肾细胞癌患者蛋白尿的危险因素：合并临床试验数据的次要分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Proteinuria is a common adverse effect of vascular endothelial growth factor targeted agents, particularly in metastatic renal cell carcinoma (mRCC). However, risk factors for proteinuria are poorly defined.

机译：背景：蛋白尿是血管内皮生长因子靶向剂的常见不良影响，特别是在转移性肾细胞癌（MRCC）中。但是，蛋白尿的危险因素的定义很差。

著录项

来源
《The British journal of cancer 》 |2016年第12期| 1313-1317| 共5页
作者
Sorich Michael J.; Rowland Andrew; Kichenadasse GanessanWoodman Richard J.Mangoni Arduino A.;
展开▼
作者单位

Flinders Univ S Australia, Sch Med, Flinders Ctr Innovat Canc, Adelaide, SA 5042, Australia;

Flinders Univ S Australia, Sch Med, Dept Clin Pharmacol, Adelaide, SA 5042, Australia;

Flinders Univ S Australia, Sch Med, Flinders Ctr Epidemiol & Biostat, Adelaide, SA 5042, Australia;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词
vasculotropin inhibitor; Proteinuria; pazopanibRisk Factorsmetastatic kidney cancersunitinibAngiogenesis InhibitorsSurvival;

机译：血管蛋白抑制剂;蛋白尿;pazopanibrisk因子对肾脏肿瘤抑制抑制剂抑制剂抑制剂抑制剂。;

相似文献

外文文献
中文文献

1. Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data [J] . Ashley M. Hopkins, Adel Shahnam, Sasha Zhang, 癌症生物学与医学（英文版） . 2019 ,第002期
2. Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data [J] . Ashley M. Hopkins, Adel Shahnam, Sasha Zhang, 癌症生物学与医学：英文版 . 2019 ,第002期
3. Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias [J] . Lim Jessica, Wang Li, Best Nicky, Therapeutic innovation & regulatory science. . 2020 ,第4期

机译：Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias
4. Stereotactic Ablative Radiotherapy versus Lobectomy for Operable Stage I Non-small-cell Lung Cancer: A Pooled Analysis of Two Randomized Trials——胸外科医生的解读 [O] . 许林 (Lin XU) 2015

机译：Stereotactic Ablative Radiotherapy versus Lobectomy for Operable Stage I Non-small-cell Lung Cancer: A Pooled Analysis of Two Randomized Trials——胸外科医生的解读
5. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma [O] . Xue Yi-Jun, Xiao Ri-Hai, Long Da-Zhi, 2012

机译：Overexpression of Foxm1 is associated with tumor progression in patients with clear cell renal cell carcinoma

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data

摘要

著录项

相似文献

相关主题

期刊订阅